Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vedolizumab shows long-term safety, efficacy

Publish date:: October 7, 2020

Key clinical point: Vedolizumab is safe and effective for long-term use in patients with inflammatory bowel disease (IBD).

Major finding: Vedolizumab was discontinued because of adverse events in 15% of patients with ulcerative colitis and 17% of those with Crohn’s disease.

Study details: GEMINI LTS was a phase 3 open-label study involving 2,243 patients with IBD.

Disclosures: GEMINI LTS was funded by Takeda. The investigators reported additional relationships with AbbVie, Amgen, Janssen, and others.

Citation:

Loftus Jr EV et al. Aliment Pharmacol Ther. 2020 Sep 2. doi: 10.1111/apt.16060.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,